remarkable the for molecules: tirzepatide, of molecules delivered next excited in lebrikizumab, patients. tenenumab, on of XXXX the and potential all years, Thank about and pirtobrutinib, a hold these you, Anat. data to was have pipeline. launch We year the which Lilly’s for X mirikizumab we potential positive are two
Verzenio our for and new we we And for important In submitted pipeline. Jardiance. also, key in-market advanced including indications launched early-stage indications addition, products, new and several
an Just innovation therapeutic the R&D from coming of a few we next update our excitement shared provided Lilly. areas about our across extensive wave weeks-ago, and
geographies today’s of recent result, As have focus Slides XX be for In January preserved of diabetes. Diabetes, We treatment the Japan, well this as potential XXXX. of on X approvals a Slide brief In a Jardiance call. for from anticipate and approval update for important XX, key shows received and as midyear. SURMOUNT-X, recap R&D have X readout the submitted now both earnings we key type regulatory opportunities last XX type major fraction. show forward and for in we to select U.S. across progress XXXX treatment pipeline reduced since year. failure for diabetes our heart Japan, submitted made We will with tirzepatide events Jardiance in ejection with and the by potential XX all events action ejection fraction submission and for heart line top failure as we with medicine this look of the
shared chronic and lymphoma. for updated pirtobrutinib both cell encouraging ASH data Moving We to mantle for at leukemia lymphocytic Oncology.
initiated chemoimmunotherapy. We and in molecule continue study another III to pirtobrutinib CLL to first-line Phase this comparing progress
initiation for excited to complete to and our meeting, medicine early this on the important also are a pirtobrutinib to regulatory We with year this bring plan U.S. patients rolling anticipated submission During XXXX, we the announced in in this this December submission timeline. potentially we accelerated MCL action of for
high-risk intent-to-treat X the For XX% received are pleased early population. represents in that the approval to we for cancer this monarchE Japan Verzenio, population study for approval breast and Cohort of
challenges. treatment We have the terminate and HERX to early decision enrollment further breast difficult the the for enrollment of to Phase global made landscape cancer in changing positive study Verzenio response III also in
Importantly, change our not breast in cancer. and decision to this commitment investment does
ulcerative announced for of of dosed and first study line adjuvant III positive we trial addition, the for our top in RET-positive for began non-small In inhibitor. also we In of BCL-X III cancer Phase mirikizumab data study maintenance in the cell our lung treatment we selpetatinib a Immunology, Phase colitis. U.S. patient the
endpoints, that secondary pleased met forward half primary and submissions the first are year. We look to the this key we study in and all of
the end await line corticosteroids, lebrikizumab first the of top for half positive for a maintenance lebrikizumab announced and topical We by results in in to XXXX. for in data date also are of expected submissions, are year We Phase with we that encouraged of treatment has advance dermatitis. III data which of competitive combination atopic global demonstrated profile this
to on efficacy last Phase results that the III baricitinib. we We Phase III trials, program from top based announced two lupus. Moving for week to discontinue decided have line development
dermatitis on the are discussions a ongoing we atopic possibly U.S., FDA, agency letter. indicated with which to the with but complete For could response the not lead have do in in the alignment population,
We this expect very regulatory for soon. action indication
alopecia IL-XX become our patients first submitted portfolio, have living hope for Phase and the phase areata disease antibody study new Finally, In oral in this year. CDXX approved U.S. it for early baricitinib and for will we I with have a discontinued immunology medicine this later our we started inhibitor. the we
pivotal lowering initiate agent that trials breakthrough to the we which have designation we end NXpGX, received intend this amyloid an of by we for Moving neurodegeneration. pipeline, to additional for year. our therapy In announced early-phase
that we are plaque cleared flexible regimens, therapy have subcutaneous evidence and completely and dosing dosing. We amyloid is exploring including this rapidly
disease, also oglic/nacase an the treatment for began oral a inhibitor, II For of tau. Alzheimer’s we trial molecule Phase targeting our small
While investors, our of rest we neurodegeneration pleased pipeline. donanemab been of the for focus continued advancement has clinical with the are primary a
expanded on III TRAILBLAZER-ALZ two positive Now less clearance since study, study, turning to which expected TRAILBLAZER-ALZ and one randomized III compared December, fully to need has we from then, function. asymptomatic for been Alzheimer’s X, than replication add-a-helm. and in to our X, we endpoints Phase prevention meaningful and controlled we focused have plaque additional of our for mid-XXXX. study It a well-designed studies, clinically now read which head-to-head investors TRAILBLAZER-ALZ TRAILBLAZER-ALZ disease; published study is cognition donanemab, Since on Phase benefits year our X, in out enrolled demonstrated the initiated
get While us year, importance a our before design. year, for happened this and and are has next results what confidence during TRAILBLAZER-ALZ both in changed top and this is study more we the unique line lot in events readout of last the hasn’t likely donanemab X the space
Given the can’t noted We of confirmatory reimbursement, data, not data that expectations and potential had for if approval believe donanemab low provides use that between is the broad patient access see during of year Phase donanemab. in III impact there and we accelerated last the positive we of of confirmatory this where disease, period availability the mid-XXXX. devastating X TRAILBLAZER-ALZ a scenario global use we
has decision, CMS Centers for TRAILBLAZER-ALZ Medicare and We are for disappointed with X the readout its could now in this determination historical position timelines draft that expectations of those reconsideration determination process. national Services some and low is required, coverage Medicaid taken coverage given the for extend months if beyond
accelerated year, approval than by instituted move out donanemab Alzheimer’s serious completion of allow conditions disease. NCD the valuable more to unmet trials, QX. is accelerated medical yet accelerated treat faster submission drugs the was patient for patients essentially benefit for of access this earlier clinical to approval for currently the that approval approval available in application the an FDA intend we hence but that need, fill pathway our of what complete Still, written under While negates is to we providing and now
unchanged. as volatility donanemab disease And long-term and We read prior We differentiation help TRAILBLAZER-ALZ in trials our designed expect opportunity with of definitive Alzheimer’s out donanemab remains confident expectations to the study. and patients X our data. uniquely to in further importantly, the remain competitor
request for severe to treatment Emergency respect mild to bebtelimumab high bebtelovimab for Use this at with moderate therapies. submitted neutralization pseudovirus Lastly, for retains authentic assays of of COVID-XX the third our variants other for of patients including COVID-XX year, as have Authorization progression progress for for treatment Earlier Omicron of known and concern. activity the all COVID-XX, virus we with risk to and a well as that death. we antibody or hospitalization demonstrate COVID-XX, against the and This developed is FDA
have doses We and supply thousand several as FDA. if from receives of ready needed antibody the hundred EUA to this produced stand bebtelovimab
baricitinib an for the action supplemental NDA and has year. a submitted by indication. with this of also EUA this patients have for Baricitinib middle regulatory of hospitalized expect we addition, for In COVID-XX treatment currently
have of part patients. behalf another emerge. was an quarter combat what for summary, COVID-XX health delivered are the of capping productive continue do at year R&D Lilly, pipeline of public and to pandemic, we In help needs the was will progress our outstanding proud as we to therapies We QX on
turn will call I Dave. the Now back to
